if longs who loaned out shares were selling as NWBO was making new highs, and shorts couldn't find replacement shares they would have been forced to close their positions
guess we should have thought about sending Dianne questions for the cc
my opinion is that Elite easily gets $10-12 million next year just from the current generics
the ones being held by FDA are frustrating, especially when companies are allowed to proceed with 'change of manufacturing location' after 30 days but nobody does because they risk being shut down after the fact when FDA finally does act
Hakim has said he wants to expand the generic side to include some big time drugs and become a major player in that arena -- and he seems ready to sell or make a deal on anything if the price is right, so maybe that is where we are headed
would be good if FDA would actually meet their advertised time frames, some of which are supposed to be hard maximums such as the 30 days they have to approve location changes which we have been courteously and cooperatively waiting on for over a year
suspect we find out on cc today why it will take until the end of the year to submit what should be fairly simple data
never been a big fan of the generics but that performance is sensational
R&D running at $20 million per quarter has pretty much burned through the $40 million from Woodford
unless Linda is waiting for an interim analysis on Phase III or final results on Phase I or something big on German reimbursement, she has to get some financing soon because if the coffers get too low she is going to lose she will not be able to get as good a deal
interesting how moaningtree claims to not be a naysayer and then proceeds to bleat nothing but negative possibilities and outcomes except for the "first of all" comment that you picked up on and which is actually highly likely, e.g., that Elite would be bought out by the second or third abuse resistant drug approval
as for the rest of his blather...
-- don't recall anyone saying that all 17 ART drugs would be launched at the same time
-- if ELI-200 is approved then it is absolutely reasonable to assume that the stock will jump, the revenues will quickly start flowing because everything will be in place for that to happen, and Hakim will have the luxury of bringing the rest of the drugs along a few at a time to coincide with revenues or to finance in order to speed up the process
-- having just completed a minimal phase III for ELI-200, there is no reason to be concerned about other phase III's involving the same technology regardless of whether FDA requires them or not
-- stocks do NOT typically "tumble below the pullback price after launch" unless serious safety concerns are revealed after launch -- though the one who cannot say 'nay' will likely find an exception or two to share with us
"This is why we're stuck in the .20s, investors are waiting to see revenue."
THAT is what you said, which means you think ELTP will stay stuck in the .20's even in the face of FDA approval
now you are trying to change the meaning of what you said to allow for ELTP to actually soar to the heights but with a caveat -- it will fall back to earth if the revenues are lousy
hmm-mm, what a brilliant statement -- imagine, a stock could actually go down if revenues disappoint
do you ever bother to read what you write before posting?
doesn't sound very abuse resistant according to the label...
"OXAYDO can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing oxycodone HCl in situations where the physician or pharmacist is concerned about an increased risk of misuse or abuse.
OXAYDO may be abused by crushing, chewing, snorting or injecting the product. These practices pose a significant risk to the abuser that could result in overdose and death"
are you back to fully loaned out, or are shorts still finding cheaper shares
don't like that folks on this board (quite a few) are loaning to them but you provide something of a gauge for how confident the shorts are when you tell us that you are fully loaned or not, and what percentage they are paying
this was a report on very preliminary work done over a year ago that involved 16 dogs, and then one patient and one tumor
do you have any update
"Worse yet, the revenue miss came from Biogen's main growth driver, multiple sclerosis drug Tecfidera. It says a lot when a 26% year-over-year increase is considered a miss; but investors were hoping that international growth in Tecfidera could take over for stalling growth in the U.S.
Part of the subpar growth in Tecfidera has to do with a lower price for the drug in Germany -- international sales fell 8% quarter over quarter despite a 14% increase in volume."
Novel bought $2 million worth of Elite stock which gave them 5% ownership at that time
have no idea when Novel sold that, or if they have
what caused elite's ownership interest to drop was that elite could not put up the remaining $20 million or provide any further matching funds due to its financial condition -- unfortunately this allowed Novel to begin unilaterally diluting elite's ownership
this may also be the reason that Gavis was created as an 'affiliate' rather than a subsidiary which meant elite's ownership in Novel did not extend to Gavis where, essentially, all the revenues and profits would reside -- but all this was done before Hakim showed up, or even Jerry
in any case, there has been bad blood between Novel and Elite for years as evidenced by Elite going to Epic for financing instead of Novel, and Novel creating Gavis instead of utilizing Elite's manufacturing facility
but, again, all of this was before Jerry and Hakim, and was caused by Elite not being unable to continue funding Novel -- blame the former management
btw, considering Hakim had started an action against Novel in April last year he sure did sound gracious when discussing the $5 million on the cc
according to this filing from eight years ago it was 49 percent, but i think it started at 50/50...
"In December 2006, Elite entered into a joint venture with VGS Pharma, LLC and created Novel Laboratories, Inc., a privately-held company specializing in pharmaceutical research, development, manufacturing, licensing, acquisition and marketing of specialty generic pharmaceuticals. Novel’s business strategy is to focus on its core strength in identifying and timely executing niche business opportunities in the generic pharmaceutical area. Elite currently holds 49% and VGS holds 51% of Novel’s capital stock. Elite initially contributed $2,000,000 to Novel in December 2006 and on May 15 and June 15, 2007, Elite contributed $2,000,000 and $3,000,000, respectively. The remaining contributions to be made by Elite in order to maintain its full equity interest in Novel equal $20,000,000.
As of June 15, 2007, Novel has 30 employees, has identified 22 generic product opportunities and is actively developing 11 generic products. It is Novel’s general policy not to disclose products in its development pipeline or the status of such products until a product reaches a stage that we determine, for competitive reasons, in our discretion, to be appropriate for disclosure."
oops, typo -- Elite's initial ownership interest was 49% not 40%
frankly, it seems it was actually 50% which would be a full partnership, but the SEC filing from back then says 49%
because Novel set up Gavis as an affiliate, Elite had no ownership interest
and because Novel created Gavis to handle manufacturing and distribution meant all the revenues and profits were parked over there, i.e., Novel was pure R&D
which may be why Hakim started an action against Novel in April of 2014 which was then dropped when he accepted the $5 million settlement
when brought up on the cc at the time, Hakim did not seem 'happy' with the settlement but basically said it was good to get that distraction behind us and move on
Elite definitely got short changed, but the problem was, after helping to fund Novel when the partnership was formed in 2007, Elite stopped making matching contributions and its ownership interest dropped from 40% to 10% such that Elite had no say it what was being done -- at least in Nevada...things might have been different if they had stayed incorporated in New Jersey
195 million shares early in 2011
don't remember exactly when the share count went up during the year but it was after the price peaked/peeked at .26
so, if the share count had not tripled, we would be around .80 but w/o the share count going up we might not even be here
according to the Form 4 the shares were distributed to its members at $0.00 per share, and Epic Investments no longer holds any Elite shares
does anyone know who the members are and how this might be affecting the price of Elite
clinicaltrials site is updates often lag behind because they are not proactive
the entries their are also ambiguous at times with respect to terms used
'so when we see 'start' or 'enrolling' and '6-8 weeks to completion' we probably should not take it all literally as it could be they have started and began contacting potential enrollees or that they have at least one person signed up who is scheduled for treatment within two weeks, or something similar, and that it will take 6-8 weeks to get results for each patient but that enrollment is not all the same day and surgery schedules could cause delays of a few weeks
bottomline is that there are a couple of hospitals and lot of patients and a lot of coordination involved, so be prepared for slippage as is always the case with trials
beta, those footnotes confirm that Cognate still has warrants for 10.5 million shares to go along with the 18.5 million actual shares they hold even after selling 1.7 million on June 30th when one of Cognate's bondholders chose to convert into NWBO shares -- Cognate alone controls 29 million shares
and we know Cognate has sold bonds before that are convertible into NWBO shares based on the warrants Cognate holds because Cognate had to pay at $441k penalty for early redemption of warrants when Cognate had to satisfy a conversion in 2014
now, there isn't any way of knowing who those bondholders were, or whether Cognate has issued any more bonds convertible into NWBO shares Cognate, or whether Cognate plans to issue more convertible bonds but...and i really, really hate to suggest it... but maybe those bondholders are shorts, and that they are getting access via Cognate's warrants to shares that are not yet even part of the float, and that these are the naked shorts Larry Smith mentioned in his article a couple months back. if so, they are not so naked at all. in fact, they have excellent, rock solid protection, and are even receiving interest for those Cognate bonds
i've been wondering where shorts are getting shares from what with Linda, Cognate, and Toucan, and Woodford and other institutions tying up so many tens of millions of shares but i'm beginning to think some of them might be getting their shares via these Cognate convertible bonds, and Cognate and/or institutions might actually be loaning their shares, or rights to shares, in exchange for short term profit while waiting for trials to be completed -- not unlike what some posters on this board have admitted to doing
what do you think?